Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 3 August 2021SV NewsPaul LaViolette describes SV's investment focus
3 August 2021Portfolio NewsMestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures
29 July 2021Portfolio NewsWellSky® to Acquire Healthify to Enhance Social Services Care Coordination Across the Continuum
29 July 2021Portfolio NewsBioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix
27 July 2021Portfolio NewsArtios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
22 July 2021SV NewsInternational Biotech looks for M&A booster shot- 19 July 2021SV NewsSV Health Investors becomes a signatory of the Investing in Women Code signifying it’s commitment to contribute to improving female entrepreneurs’ access to tools, resources and finance.
13 July 2021Portfolio NewsBicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
6 July 2021Portfolio NewsSitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement
5 July 2021Portfolio NewsTransine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
2 July 2021Portfolio NewsGSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
24 June 2021SV NewsAARP celebrates DDF's three-year anniversary of the final close of the Fund
